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Summary
Objective: To determine the effect of avian chondroitin sulfate (CS) on interleukin-1b (IL-1b)-induced expression of genes related to catabolic,
anabolic and inﬂammatory aspects in chondrocytes cultured in hypoxic alginate beads.
Design: Articular chondrocytes from bovine metacarpal joint were isolated and cultured in alginate beads, using low oxygen atmosphere (5%
O2). After 1-week exposure to CS (1, 10 and 100 mg/ml), they were treated by recIL-1b (10 ng/ml) for 24 or 48 h, in the presence of CS. RNA
was extracted and used to determine, by quantitative reverse transcription-polymerase chain reaction, the steady-state levels of mRNAs
encoding several genes related to anabolic, catabolic and inﬂammatory aspects. Glycosaminoglycan (GAG) synthesis was also assayed
by 35S-sulfate incorporation.
Results: CS decreased IL-1b-induced expression of matrix metalloproteases-1, -3 and -13 and aggrecanases-1 and -2. It slightly enhanced
the aggrecan core protein mRNA and the GAG synthesis. Inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) mRNA levels
were found to be reduced by CS treatment. However, no CS-induced decrease of NO was observed in IL-1b-treated chondrocytes, whereas
prostaglandin E2 production was diminished in correlation with the COX-2 mRNA amounts. Furthermore, CS was capable of counteracting
IL-1b-depressed expression of transforming growth factor-b (TGF-b) receptors.
Conclusions: CS can repress expression of genes encoding proteolytic enzymes involved in cartilage degradation. It also inhibits IL-1b-
induced expression of the pro-inﬂammatory genes iNOS and COX-2 and restores TGF-b receptors I and II (TGF-bRI and RII) mRNA levels.
These data suggest that CS may exert both chondroprotective and anti-inﬂammatory limited effects on articular cartilage that could have long-
term beneﬁcial action on the osteoarthritic process.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Key words: Chondroitin sulfate, Interleukin-1, Chondrocytes, Gene expression.Introduction
Chondroitin sulfate (CS) is a glycosaminoglycan (GAG),
extracted and puriﬁed from various tissues, with polysac-
charide chains composed of an alternated sequence of
D-glucuronic acid and D-N-acetyl galactosamine residues,
associated by b(1/ 3) and b(1/ 4) links. Depending on
the source, different non-sulfated and sulfated disaccha-
rides units are present within the polysaccharide chains1.
CS is a major class of GAG, which is widely distributed in
all tissue extracellular matrices where it forms an essential
component of proteoglycans by covalent links with proteins2.
Because of their high degree of hydration, the CS-containing
proteoglycans of articular cartilage are responsible for the
visco-elastic properties of the tissue. Thus, their profound
alteration in the articular cartilage of patients suffering from
osteoarthritis (OA) results in great functional impairment3.1This work has been supported by Pierre Fabre Laboratories
(Castres, France).
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105The therapeutic use of GAG and mixtures of different
polysaccharides has been markedly developed in the re-
cent years, due to a better knowledge on their structural, bi-
ological and pharmacological properties. CS is used as
a chondroprotective drug4 and is administered in the treat-
ment of OA, mainly by oral route, with some improvement
of joint functions5e9. However, the cellular and molecular
mechanisms underlying the symptomatic effects of CS in
OA treatment remain largely unknown. Some insights into
these mechanisms can be deduced from in vitro experi-
ments performed on articular cartilage explants or isolated
chondrocytes, albeit they do not allow extrapolation to the
in vivo situation. CS stimulates the proteoglycan synthesis
of bovine and human chondrocytes10. Furthermore, some
anti-inﬂammatory properties have been attributed to CS,
based on its ability to inhibit human leukocyte chemotaxis
and phagocytosis, and to protect plasma membrane from
oxygen reactive species11. Recently, in vitro data support-
ing the potential chondroprotective and anti-inﬂammatory
effects of CS have been also reported12,13. However, the
cellular and molecular mechanisms of these actions still re-
main to be elucidated. In the present study, we used for the
ﬁrst time, hypoxic alginate bead cultures to investigate the
effects of CS on bovine chondrocytes, in order to better sim-
ulate the in vivo living conditions of chondrocytes. The ex-
pression activity of several genes, related to catabolic and
106 F. Legendre et al.: CS modulation of matrix and inﬂammatory gene expressionanabolic aspects of the extracellular matrix, as well as in-
ﬂammatory process, was determined at the transcriptional
level.
MethodsCULTURE AND TREATMENT OF ARTICULAR CHONDROCYTESMost of our experiments were performed on chondro-
cytes derived from the knee joints of freshly slaughtered
calves. However, additional experiments were also per-
formed on chondrocytes derived from adult retired cows
(more than 10 years old). Chondrocytes were enzymatically
isolated by digestion with type XIV protease (4 mg/ml;
SigmaeAldrich Co., St Quentin Fallavier, France) for 1.5 h
and type I collagenase (1 mg/ml; SigmaeAldrich Co.) over-
night in Dulbecco’s modiﬁed Eagle’s medium (DMEM, Life
Technologies, Inc., Cergy Pontoise, France) at 37C. Cell
culture was then performed in hypoxic conditions (5% O2),
using solutions previously equilibrated at 5% O2 by bubbling
a gasmixture deprived of oxygen. The cells were then encap-
sulated in alginate beads at a density of 0.75 106 cells/ml
of low viscosity alginate gel (Sigma, 1.25% in HEPES
(N-(2-Hydroxyethyl)piperazine-N 0-(2-ethanesulfonic acid)
20 mM, NaCl 0.9%) as previously described14. The culture
ﬂasks were placed inside a special plastic chamber, in
hypoxic atmosphere (5% O2), with DMEM previously equili-
brated to 5% O2 by gas bubbling and containing 10% fetal
calf serum (FCS), 50 mg/ml sodiumascorbate and antibiotics.
The beads were maintained in 75-cm2 ﬂask (4.5 106 cells/
ﬂask) for RNA extraction and in six-well plates in triplicate
(1.5 106 cells/well) for assay of GAG neosynthesis. On
day 8, the beads were incubated with 10% FCS-containing
medium with CS (avian CS 1, 10 or 100 mg/ml, average
MW 18 kDa, less than 1.5% protein contaminant; Pierre
Fabre Laboratories, France) and medium changes were
done every 2e3 days, each set of wells having the same
medium replacement protocol. On day 13 or 14, interleukin-
1b (IL-1b) (10 ng/ml; generous gift from Dr Soichiro Sato,
Shizuoka, Japan) was added until day 15.RNA EXTRACTION AND REAL-TIME POLYMERASE CHAIN
REACTION (PCR) CONDITIONSOn day 15, the beads were dissolved in Na citrate/EDTA
(Ethylenediaminetraacetic acid disodium salt) solutionTable
PCR primers used
Gene Sense primer from 50 to 30
Aggrecan TCG AGG ACA GCG AGG CC
Aggrecanase-1 CCG CTT CAT CAC TGA CTT CCT
Aggrecanase-2 AGC GCT TAA TGT CTT CCA TCC T
Type II collagen GCA TTG CCT ACC TGG ACG AA
COX-1 TCA GCA CCC AGC AAA TCC T
COX-2 GCA CCAATC TGA TGT TTG CAT TC
IL-1b TCT CCG ACC ACC ACT ACA GCA A
iNOS GGC CCA GGA AAT GTT CGA A
MMP-1 GAC CAG CAA TTT CCA AGA TTA TA
MMP-3 TAC GGG TCT CCC CCA GTT TC
MMP-13 TTC TTC TGG CGG CTG CAT
TGF-bRI TTA AAA GGC GCA ACC AAG AAC
TGF-bRII GGA GCG GAA GAC GGA GTT G
TGF-b1 CAT CTG GAG CCT GGA TAC ACA G
TGF-b2 CTG TGT GCT GAG CGC TTT T
TGF-b3 CAA TTA CTG CTT CCG CAA CTT G
18S CGG CTA CCA CAT CCA AGGAA(55 mM Na citrate, 25 mM EDTA, in 150 mM NaCl) for
15 min at 37C and the cells were collected. Total RNA
was extracted from the cellular pellet by the guanidium iso-
thiocyanateephenolechloroform procedure15. Following
extraction, 1 mg of DNase I-treated total RNA was reverse
transcribed at 37C for 1 h. The reaction was stopped by
heat inactivation (90C for 15 min), and the resulting prod-
ucts were then diluted (1/100) before ampliﬁcation.
Oligonucleotide primers were designed from human or
bovine sequences using Primer Express software (Applied
Biosystems, Foster City, CA, USA), within highly conserved
regions of each complementary DNA (cDNA). BLASTN
Basic Logarithmic Alignment Search Tool for Nucleotides
searches were conducted on primer nucleotide sequences
to ensure gene speciﬁcity (Table I).
Ampliﬁcations were carried out in triplicate, using 96-well
optical plates and following all instructions of the ABI Prism
7000 SDS apparatus (Applied Biosystems). Brieﬂy, 5 ml of
diluted cDNA was mixed with both forward and reverse
primers and 2 SYBR Green PCR Master Mix (Applied
Biosystems) in a ﬁnal volume of 15 ml. Cycling parameters
were as follows: one cycle at 95C for 10 min and 40 two-
segment cycles for ampliﬁcation (95C for 10 s and 60C
for 1 min), and a dissociation protocol which is deﬁned as
a hold at 95C for 15 s, a hold at 60C for 20 s, and
a slow ramp (20 min) from 60C to 95C. Single peaks
were conﬁrmed in PCR to exclude non-speciﬁc ampliﬁca-
tion, using this dissociation protocol. Serial dilutions of
cDNA were also ampliﬁed to establish a standard curve
and to determine the corresponding threshold cycle (CT).
The 18S RNA gene was used as an endogenous control
to normalize for differences in the amount of total RNA in
each sample. The relative gene expression was calculated
with the 2DDCT method or the standard curve method de-
pending on the efﬁciency of the ampliﬁcation of each 18S
RNA and target gene16.ASSAY OF GAG NEOSYNTHESIS BY 35S-SULFATE
INCORPORATIONOn day 14, 35S-sulfate (3 mCi/ml; PerkinElmer Life Sci-
ences) was added for 24 h to assay GAG neosynthesis.
The medium was collected and frozen for further analysis
of NO and prostaglandin E2(PGE2) amounts. The beads
were then washed to remove free 35S-sulfate and frozenI
in this study
Antisense primer from 50 to 30
TCG AGG GTG TAG CGT GTA GAG A
GGA GCC TCC GGC TTG TCT
GTG GCT GAG GTG CAT TTG G
CGT TGG AGC CCT GGATGA
GTG ATC TGG ATG TCA GCA CG
GGT CCT CGT TCAAAA TCT GTC TTG
GGG GAA CTG GGC AGA CTC A
ACC TGA TGT TGC CGT TGT TG
A CTT CCA AGG GAA TGG CCA AA
GGT TCG GGA GGC ACA GAT T
GGA AGT TCT GGC CCAAAC G
GTG GTG ATG AGC CCT TCG AT
GAC ATG CCG CGT CAG GTA CT
T GAA GCG CCC GGG TTG T
CGA GTG TGC TGC AGG TAG TCA
GAT CCT GTC GGA AGT CAA TGT AGA
GCT GGAATTACC GCG GCT
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107Osteoarthritis and Cartilage Vol. 16, No. 1until analysis. Samples were subjected to papain digestion
for 18 h at 65C (25 mg/ml in 50 mM sodium phosphate
buffer containing 2 mM N-acetyl cysteine and 2 mM EDTA
adjusted to pH 6.5)17. Aliquots of papain digest were used
for sulfate incorporation measurements, after Alcian blue
precipitation18, in a liquid scintillation counter. dsDNA quan-
tiﬁcation was also performed to normalize sulfate incorpora-
tion among cultures, using a picogreen dsDNA assay kit
(Life Technologies, Inc.). The culture medium was not as-
sayed for its GAG content since previous reports showed
that this fraction was negligible in alginate bead cultures
(2e4% of the total amount)14,17.R
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Nitrite levels were measured in conditioned media, using
the Griess reagent and sodium nitrite as a standard19.
Brieﬂy, 100 ml medium was incubated with 100 ml of 0.5%
sulfanilamide, 0.1% N-1-naphthylenediamide hydrochloride
and 2.5% phosphoric acid at room temperature for 5 min in
96-well plates. Absorbance was measured at 540 nm using
a spectrophotometer plate reader. NO production was
normalized among cultures with dsDNA quantitation.0
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using a commercially available competitive enzyme immu-
noassay kit (R&D Systems). Absorbance was determined
at 450 nm with a wavelength correction set at 540 nm.
PGE2 production was normalized among cultures with
dsDNA quantitation.5
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Fig. 1. Effect of CS on IL-1b-induced MMP and aggrecanase
mRNA expression. Chondrocytes were treated for 7 days in theAt least three identical experiments were performed, us-
ing chondrocytes from different samples, which were found
to give the same effects, but with variable amplitudes. The
data from a representative one are shown as means stan-
dard deviation (SD) (PCR) or standard error of mean
(S.E.M.) (35S incorporation, NO and PGE2 assay) of three
wells per point. Statistical signiﬁcance was determined by
Student’s t test using Bonferroni correction for multiple
group comparisons (corrected P-values: *P< 0.05,
**P< 0.01, and ***P< 0.001).presence or absence of CS (1, 10, or 100 mg/ml). IL-1b (10 ng/ml)
was added for the latest 24 or 48 h. Total RNA was extracted
and used in quantitative PCR to determine steady-state mRNAResults
levels of MMP-1 (A), MMP-3 (B), MMP-13 (C), aggrecanase-1 (D)
and aggrecanase-2 (E). Data were normalized to 18S mRNA and
expressed as meansSD of triplicate samples. Statistical signiﬁ-EFFECTS OF CS ON MATRIX METALLOPROTEINASE (MMP)
AND AGGRECANASE mRNA LEVELScance of difference between control and IL-1b treated cells, and
between control, IL-1b 24 h or IL-1b 48 h and cells treated with
CS was determined, using the Student’s t test with Bonferroni
correction within each group of comparisons (corrected P-values:
*P< 0.05, **P< 0.01, and ***P< 0.001).Chondrocytes were treated during 7 days with increasing
concentrations of CS (1, 10 and 100 mg/ml) and with IL-1b
for the latest 24 or 48 h. To determine the steady-state
mRNA levels of various degradative enzymes (MMP-1, -3
and -13, and aggrecanases-1 and -2), the cells were lysed
and the RNA was extracted (Fig. 1). Real-time reverse tran-
scription-PCR (RT-PCR) revealed that CS did not signiﬁ-
cantly alter the basal levels of MMP-1, -3, and -13 and
aggrecanases-1 and -2 mRNAs, whatever the concentra-
tion of CS used.
As expected, IL-1b (24 and 48 h) stimulated the expres-
sion of all these enzyme genes. Pretreatment with CS
(1, 10 or 100 mg/ml) decreased the up-regulation of MMP-
1 mRNA (by 22% to 32%) and aggrecanase-1 mRNAs
(20% to 40%) induced by a 24-h incubation with IL-1b.In addition, CS was also able to reduce IL-1b-induced
mRNA levels of these ﬁve degradative enzymes after
48 h, generally at the concentrations of 50 and 100 mg/ml.
Thus, CS (100 mg/ml) slightly inhibited the up-regulation of
MMP-1 mRNA level (19%). CS (10 and 100 mg/ml) also
reduced the increase of MMP-3, -13 and aggrecanase-1
mRNA expression and ﬁnally CS (1 and 10 mg/ml) re-
pressed the IL-1b-induced up-regulation of aggrecanase-2
gene.
108 F. Legendre et al.: CS modulation of matrix and inﬂammatory gene expressionEFFECTS OF CS ON THE EXPRESSION OF IL-1b, INDUCIBLE
NITRIC OXIDE SYNTHASE (INOS), AND CYCLOOXYGENASE-1/-2
(COX-1/-2)We examined whether CS could modulate the expression
of inﬂammatory genes implicated in joint diseases, including
IL-1b, iNOS, COX-1, and COX-2 (Fig. 2). As expected,
IL-1b (24- and 48-h incubation) induced a stimulatory effect
on the mRNA levels of all these genes. CS had no signiﬁ-
cant effect on the basal mRNA levels of these genes. How-
ever, the IL-1b-enhanced COX-1, COX-2 and iNOS mRNA
amounts were decreased by pretreatment with CS. Con-
centrations of 10 and 100 mg/ml CS decreased the up-reg-
ulation of iNOS and COX-2 mRNA levels induced by 24-h
incubation with IL-1b (from 30% to 50% of inhibition).0
0
0
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Fig. 2. Effect of CS on IL-1b-induced pro-inﬂammatory gene ex-
pression. Chondrocytes were treated for 7 days in the presence
or absence of CS (1, 10, or 100 mg/ml). IL-1b (10 ng/ml) was added
for the latest 24 or 48 h. Total RNA was extracted and used in quan-
titative PCR to determine steady-state mRNA levels of IL-1b (A),
iNOS (B), COX-1 (C), and COX-2 (D). Data were normalized to
18S mRNA and expressed as meansSD of triplicate samples.
Statistical signiﬁcance of difference between control and IL-1b
treated cells, and between control, IL-1b 24 h or IL-1b 48 h and cells
treated with CS was determined, using the Student’s t test with
Bonferroni correction within each group of comparisons (corrected
P-values: *P< 0.05, **P< 0.01, and ***P< 0.001).COX-1 and COX-2 mRNA amounts induced by a 48-h incu-
bation with IL-1b were found to be diminished by treatment
of cells with 10 or 100 mg/ml CS (31% and 25%,
respectively).EFFECTS OF CS ON EXPRESSION OF TYPE II COLLAGEN
AND AGGRECAN CORE PROTEINSince IL-1b down-regulates type II collagen and aggre-
can synthesis in chondrocytes20,21, we investigated the ef-
fects of CS on the levels of type II collagen and aggrecan
core protein mRNA produced in IL-1b-treated chondrocytes
(Fig. 3). In agreement with the literature, we found that IL-1b
decreased type II collagen and aggrecan core protein ex-
pression. CS treatment did not have signiﬁcant effect on
basal and IL-1b-induced levels of type II collagen mRNA.
In contrast, both 10 and 100 mg/ml CS were found to slightly
increase aggrecan core protein expression but the incre-
ment was only statistically signiﬁcant for 100 mg/ml. These
CS concentrations also exerted a repression on the IL-1b
down-regulation of the gene at 24- and 48-h incubation.
However, this effect was found signiﬁcant for the value
obtained for 100 mg/ml CS and at 24 h.EFFECTS OF CS ON THE TRANSFORMING GROWTH FACTOR-b
(TGF-b) SYSTEMGiven that TGF-b plays a crucial role in cartilage homeo-
stasis22e25, it was of interest to determine the effects of CS
on the expression of the main TGF-b isoforms and their re-
ceptors I and II (Fig. 4). We observed that 10 mg/ml CS sig-
niﬁcantly increased the basal level of TGF-b2 mRNAR
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Fig. 3. Effect of CS on the expression of cartilage speciﬁc markers.
Chondrocytes were treated for 7 days in the presence or absence
of CS (1, 10, or 100 mg/ml). IL-1b (10 ng/ml) was added for the lat-
est 24 or 48 h. Total RNA was extracted and used in quantitative
PCR to determine steady-state mRNA levels of type II collagen (A)
and aggrecan core protein (B). Data were normalized to 18S
mRNA and expressed as meansSD of triplicate samples. Statisti-
cal signiﬁcance of difference between control and IL-1b treated cells,
and between control, IL-1b 24 h or IL-1b 48 h and cells treated with
CSwas determined, using the Student’s t test with Bonferroni correc-
tion within each group of comparisons (corrected P-values:
*P< 0.05, **P< 0.01, and ***P< 0.001).
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Fig. 4. Effect of CS on the expression of TGF-bs and their receptors.
Chondrocytes were treated for 7 days in the presence or absence of
CS (1, 10, or 100 mg/ml). IL-1b (10 ng/ml) was added for the latest 24
or 48 h. Total RNA was extracted and used in quantitative PCR to
determine steady-state mRNA levels of TGF-b1 (A), TGF-b2 (B),
TGF-b3 (C), TGF-bRI (D), and TGF-bRII (E). Data were normalized
to 18S mRNA and expressed as meansSD of triplicate samples.
Statistical signiﬁcance of difference between control and IL-1b
treated cells, and between control, IL-1b 24 h or IL-1b 48 h and cells
treated with CS was determined, using the Student’s t test with
Bonferroni correction within each group of comparisons (corrected
P-values: *P< 0.05, **P< 0.01, and ***P< 0.001).
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Fig. 5. Effect of CS on GAG neosynthesis. Chondrocytes were
treated for 7 days in the presence or absence of CS (1, 10, or
100 mg/ml). IL-1b (10 ng/ml) was added for the latest 24 or 48 h.
GAG neosynthesis, measured by 35S-sulfate incorporation, was
normalized to deoxyribonucleic acid content and expressed as
means S.E.M. of triplicate samples. Statistical signiﬁcance of dif-
ference between control and IL-1b treated cells, and between con-
trol, IL-1b 24 h or IL-1b 48 h and cells treated with CS was
determined, using the Student’s t test with Bonferroni correction
within each group of comparisons (corrected P-values: *P< 0.05,
**P< 0.01, and ***P< 0.001).
109Osteoarthritis and Cartilage Vol. 16, No. 1(þ50%) and that of TGF-bRI (þ46%) at the concentration of
100 mg/ml. 24-h incubation with IL-1b decreased the ex-
pression of all genes. CS slightly reduced the cytokine
down-regulation of TGF-b1 and TGF-b2 mRNA and totally
prevented that of the TGF-bRI and RII genes. A 48-h incu-
bation with IL-1b only depressed the expression of TGF-b1,
TGF-b3 and TGF-bRII. CS (10 and 100 mg/ml) was capable
of preventing this effect only on TGF-bRII gene, restoring
the control value. However, the effect was statistically sig-
niﬁcant for 100 mg/ml only.EFFECTS OF CS ON GAG NEOSYNTHESISWe examined GAG neosynthesis in alginate beads using
35S-sulfate incorporation17 (Fig. 5). CS had no effect on the
basal incorporation of 35S-sulfate in the GAG of proteogly-
cans. After 24-h incubation, IL-1b induced a small diminu-
tion of 35S-sulfate incorporation, whereas CS (10e100 mg/
ml) slightly inhibited this reduction. CS did not signiﬁcantly
repressed the IL-1b inhibition of GAG synthesis after 48 h
of incubation.EFFECTS OF CS ON NO AND PGE2 PRODUCTIONWe quantiﬁed the NO and PGE2 production into the con-
ditioned media after CS and IL-1b treatment [Fig. 6(A)]. No
signiﬁcant change was observed in the CS treated cultures,
whenever IL-1 was present or not. These data indicate that
no correlated decrease of NO production is associated to
the signiﬁcant decrease of iNOS mRNA steady-state levels.
CS had no effect on the basal PGE2 release [Fig. 6(B)].
As expected, 24- and 48-h incubations with IL-1b elevated
this basal level by 5.5- and 32-fold, respectively. CS at 10
and 100 mg/ml was found to reduce this stimulation only in
the 48-h incubation with IL-1b (from 24% to 45% of inhi-
bition). However, the effect was statistically signiﬁcant for
100 mg/ml CS only. Thus, in contrast to NO production,
PGE2 release was correlated to the COX-1/-2 mRNA levels,
although with some delay.EFFECTS OF CS ON CHONDROCYTES FROM AGED JOINTSSince there may be signiﬁcant differences in the re-
sponse of young vs aged chondrocytes to IL-1 and CS,
we performed similar experiments on cultures of cells ob-
tained from old retired cows. We focused on the main genes
which expression was found to be signiﬁcantly altered by
IL-1 and CS in the previous study on calf-derived cells.
The concentration of 10 mg/ml CS was selected as repre-
senting a mean value, which is also close to serum levels
found in patients receiving CS orally.
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Fig. 6. Effect of CS on NO and PGE2 synthesis. Chondrocytes were
treated for 7 days in the presence or absence of CS (1, 10, or
100 mg/ml). IL-1b (10 ng/ml) was added for the latest 24 or 48 h.
NO (A) and PGE2 (B) release were normalized to deoxyribonucleic
acid content and expressed as means S.E.M. of triplicate samples.
Statistical signiﬁcance of difference between control and IL-1b
treated cells, and between control, IL-1b 24 h or IL-1b 48 h and
cells treated with CS was determined, using the Student’s t test
with Bonferroni correction within each group of comparisons (cor-
rected P-values: *P< 0.05, **P< 0.01, and ***P< 0.001).
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Fig. 7. Effect of CS on gene expression in chondrocytes from adult
cows. Chondrocytes derived from adult cows were treated for 7
days in the presence or absence of CS (10 mg/ml). IL-1b (10 ng/ml)
was added for the latest 24 or 48 h. Total RNA was extracted and
used in quantitative PCR to determine steady-state mRNA levels
of aggrecan (A), TGF-b2 (B), MMP-1 (C), and COX-1 (D). Data
were normalized to 18S mRNA and expressed as meansSD of
triplicate samples. Statistical signiﬁcance of difference between
control and IL-1b treated cells, and between control, IL-1b 24 h or
IL-1b 48 h and cells treated with CS was determined, using the
Student’s t test (*P< 0.05, **P< 0.01, and ***P< 0.001).
110 F. Legendre et al.: CS modulation of matrix and inﬂammatory gene expressionAs can been seen in Fig. 7(A), CS treatment for 24 h in-
duced a signiﬁcant increase of aggrecan core protein
mRNA (approximatively twofold), indicating that the re-
sponse of this gene to CS was comparable to that found
in young chondrocytes, and even greater [see Fig. 3(B)].
In the presence of IL-1b, CS was also capable to oppose
the cytokine inhibition. Moreover, the stimulative effect ob-
served was greater than in young chondrocytes [4.5-fold,
compared to 0.5 in Fig. 3(B)] and even overcomes the con-
trol value (without IL-1b). Similar data were obtained for the
expression of TGF-b2, the growth factor isoform which was
clearly responsive to CS treatment in young cells [Fig. 7(B),
compared to Fig. 4(B)]. Regarding the response of MMP-1
gene, it must be noted ﬁrst that IL-1b induced a lower stim-
ulation of the mRNA level in old vs young cells [threefold
compared to eightfold increase in Fig. 1(A)]. Furthermore,
this effect could be observed at 48 h rather than 24 h for
calf-derived chondrocytes (24 h results for old cow chondro-
cytes not shown). In these conditions, CS elicited a clear in-
hibition of the IL-1-induced MMP-1 expression, which was
greater than in the corresponding experiments with young
chondrocytes [compare Fig. 1(A) to 7(A)]. Similarly, signiﬁ-
cant effect of CS on COX-1 gene occurred after 48 h. These
data suggest that IL-1-responsive genes related to both ma-
trix anabolism and catabolism, as well as pro-inﬂammatory
genes, may be more sensitive to CS treatment in old vs
young chondrocytes.Discussion
In the present study, we used articular chondrocytes en-
trapped in alginate beads and maintained in low oxygen
level (5%), to better mimic the in vivo situation and to pre-
vent dedifferentiation of the chondrocytes14,26. Chondro-
cytes are well adapted to cartilage low oxygen tension,
which varies from 1% to 6% according to the tissue depth27.
Therefore, the responses to IL-1b and CS in the present cul-
ture conditions are likely to reﬂect those of the resident
chondrocytes. However, a limitation of our study was that
the alginate bead procedure requires a great number of
cells, so that it was difﬁcult to also use human OA chondro-
cytes, which would have been more representative of the
111Osteoarthritis and Cartilage Vol. 16, No. 1pathology. Nevertheless, we tried to mimic the OA situation
by stimulating the chondrocytes with IL-1b, as a key-cyto-
kine of that disease. In addition, we also performed analy-
ses on chondrocytes from old cows to determine their
sensitivity to CS, as compared to that of calf-derived cells.
MMP-1 can degrade collagen, MMP-3 cleaves proteogly-
cans, collagens, and aggrecan link protein, MMP-13 has
particular afﬁnity for type II collagen but can also cleave ag-
grecan28. OA synovia have elevated MMP-3 mRNA29. IL-1b
preferentially induces MMP-3 expression in human carti-
lage30 and MMP-3 mRNA is elevated in the cartilage of
damaged human knee and ankle31. MMP-13 from chondro-
cytes selectively enhances degradation of type II collagen
in OA cartilage32 and aggrecan at speciﬁc sites28. Human
OA cartilage has elevated MMP-13 expression, that can
be induced by IL-1b and tumor necrosis factor-a (TNF-a)
in chondrocytes33,34. Our data show that the expression
of most of the matrix-degrading enzymes produced by
IL-1b-stimulated chondrocytes could be slightly, but signiﬁ-
cantly reduced by CS treatment. The transcriptional re-
sponse of these genes as a function of time (24 vs 48 h)
and CS concentration was found to vary. For example,
MMP-1 mRNA levels were signiﬁcantly decreased in
a 24-h incubation with all the CS concentrations tested,
whereas only the highest level of CS was found to signiﬁ-
cantly reduce this amount in the 48-h period. On the other
hand, both IL-1b-induced MMP-3 and MMP-13 mRNA
levels were signiﬁcantly diminished after the 48-h time pe-
riod only. This differential time and concentration responses
of the enzymes are probably related to differences in the
control mechanisms regulating the transcription machinery
of their respective genes. The mechanisms whereby IL-1b
induces the expression of MMPs are not fully known. How-
ever, IL-1b up-regulation of MMP-3 and MMP-13 in
chondrocytes involves multiple mechanisms, including acti-
vation of ERK Extracellular regulated kinases, p38 and JNK
Jun-N kinase MAPK Mitogen-activated protein kinase
pathways as well as AP-1 Activating protein-1 and NF-kB
Nuclear factor kappa B transcription factors35. Work is in
progress to determine the inﬂuence of CS on IL-1b signal-
ing pathways in chondrocytes, and to better understand
these differential effects.
Our results are in agreement with previous data showing
that CS down-regulated the expression of MMP-3 and
MMP-13 in bovine cartilage explants12. This suggests that
CS exerts similar effects on chondrocytes in both alginate
beads and natural explant matrix. Similarly, CS
(10e1000 mg/ml) was capable of inhibiting MMP-3 synthe-
sis in IL-1b treated human OA chondrocytes36. More re-
cently, the ability of CS, alone or with glucosamine, to
reverse ﬁbronectin mediated cartilage damage through re-
duction of MMP-3 and MMP-13 expression, has been also
demonstrated37. All the preceding studies were performed
with CS from bovine origin. Interestingly, our present ﬁnd-
ings indicate for the ﬁrst time that chicken-derived CS
exhibits similar properties.
Besides MMPs, a distintegrin and metalloproteinase with
thrombospondin sequences aggrecanases-1 (ADAMTS4)
and -2 (ADAMTS5) have been found in human OA synovial
ﬂuid and joint cartilage, together with MMP-generated ag-
grecan fragments38. Furthermore, a key role of aggreca-
nase-2 (ADAMTS5) in OA cartilage breakdown has been
suggested by gene knock out of the enzyme, which pre-
vented cartilage degradation in a murine model of OA39.
In addition, it has been recently proposed that ADAMTS-
mediated aggrecanolysis is preferentially destructive to car-
tilage function whereas MMP-mediated aggrecanolysiscould be responsible for a slow turnover process of a sepa-
rate pool of proteoglycans, and therefore may actually be
beneﬁcial40. Interestingly, we found that aggrecanase-1 ex-
pression was down-regulated by CS as early as 24 h, and
that of aggrecanase-2 at 48 h, suggesting that CS could ef-
fectively reduce the transcription of these key enzymes in
chondrocytes.
The steady-state level of IL-1bmRNAwas not signiﬁcantly
modulated by CS. In contrast, the levels of IL-1b-iNOS
mRNA were clearly reduced by the CS treatment, at 10
and 100 mg/ml. Nitric oxide is induced by IL-1b in chondro-
cytes41 and reduces the synthesis of cartilage macromole-
cules42 while it enhances their catabolism43. However, this
effect was not accompanied by concomitant reduction in
NO released in the culture medium. This ﬁnding correlates
with previous data from Chan et al.12,13, which reported
only small decrease of NO by CS after a 24 h with IL-1b
and no change after 48 h. As a possible explanation for
these differences between iNOS mRNA steady-state levels
and NO production, we may suggest that CS could inﬂuence
the regulation of iNOS mRNA stability or/and the iNOS pro-
tein stability. Both human and murine iNOS 30-untranslated
region (30-UTR) contain adenylate-uridylate (AU)-rich ele-
ments that are related to destabilization of mRNA of tran-
siently expressed proteins44,45. AU-binding proteins either
promote or prevent exonucleolytic degradation of mRNA
by the exosome protein complex and thus reﬁne the effect
of (AV)-rich elements mRNA stability. In this regard, HuR
Human antigen R is a ELAV (embryonic lethal abnormal
vision)-like protein which binds a (AU)-rich element in the
30-UTR of human iNOS mRNA and stabilizes iNOS46. After
iNOS protein is expressed, it may be directed to enhanced
degradation under certain conditions. For example, TGF-
b inhibits IL-1b-induced NO production and iNOS expression
by enhancing iNOS protein degradation in chondrocytes
probably via proteasomes47. Further investigation is re-
quired to determine whether CS may inﬂuence some of
these mechanisms.
In contrast, there was a correlation between COX-2
mRNA levels and PGE2 production, after treatment with
IL-1b. PGE2 is produced in high amounts in osteo-articular
diseases, and mediates inﬂammation, tissue destruction
and inﬂammatory pain. COX-1 is constitutively expressed
and produces low physiological levels of prostanoids,
whereas the expression of the inducible isoform, COX-2,
is increased in response to pro-inﬂammatory cytokines.
COX-2 is highly expressed in RA rheumatoid arthritis and
OA cartilage48, and IL-1b enhances COX-2 expression in
articular chondrocytes49. The present ﬁndings are in agree-
ment with a previous study that showed CS-induced de-
crease of both COX-2 mRNA levels and PGE2 production
in cultured cartilage explants13. They can also be related
to the fact that oral administration of CS in rats was found
to reduce granuloma formation, as well as cell migration
and lysosomal enzyme release in carrageenan pleurisy11.
In contrast, it has been reported that the inﬂuence of CS
(5e50 mg/ml) on pretranslational regulation of these se-
lected genes was limited or lacking50. No clear explanation
can be given for such a discrepancy. It may be due to differ-
ences in chondrocytes from various species or culture
techniques (monolayer, pellet, tri-dimensional gels, and
explants).
Our study showed that proteoglycan expression was
slightly modulated by CS. The production of proteoglycans
involves several sequential steps, from the core protein
gene transcription to the enzymatic synthesis and addition
of GAG chains to the protein. Each of them could potentially
112 F. Legendre et al.: CS modulation of matrix and inﬂammatory gene expressionbe a target for CS modulation. Our ﬁndings suggested that
both transcription of the core protein gene and sulfate incor-
poration in the neo-synthesized GAG chains are slightly up-
regulated by CS treatment of chondrocytes. CS was also
capable of counteracting the IL-1b-induced decrease of
the core protein mRNA levels and GAG synthesis. This con-
ﬁrms previous study10, and could provide a partial explana-
tion for the chondroprotective properties of CS.
Changes in the TGF-b system of OA cartilage may
greatly contribute to the irreversible process of joint degra-
dation. TGF-bRII expression in articular cartilage was found
to be dramatically depressed in the rabbit OA model23. A
key role of that receptor in cartilage is further supported
by the fact that transgenic mice expressing an inactive
TGF-bRII develop joint lesions similar to human OA symp-
toms24. These data suggest that OA cartilage breakdown
involves reduced responsiveness of chondrocytes to
TGF-b25. Importantly, our results clearly showed that CS
could antagonize the IL-1b down-regulation of both
TGF-bRI and RII mRNA levels. This suggests that CS
may contribute to maintain or restore the chondrocyte sen-
sitivity to TGF-b and, therefore, their capacity to counteract
the deleterious effects of IL-1b.
There are signiﬁcant differences in the response to IL-1 of
young vs aged chondrocytes. Similarly, cartilage tissue also
does not display the same response to CS, depending on
whether it comes from young or old animals51. Tissues
from young animals were found rather refractory to CS-
induced metabolic changes. In addition, cartilage derived
from OA joints seems more responsives to polysulfated
GAG than normal joints52. Our study also showed differ-
ences between the sensitivity of genes to CS modulation
depending on the age. In adult chondrocytes, greater re-
sponses were observed for all IL-1-modulated genes. In
other words, adult chondrocytes from old animals are ap-
parently less responsive to IL-1 than cells derived from
young ones, and are more sensitive to CS treatment. How-
ever, the responses were of the same type.
To evaluate the physiopathological relevance of the
in vitro studies on CS, we may tentatively compare the con-
centrations used to those that may be achieved in OA
patients orally treated with CS. Although the intestinal ab-
sorption of CS is still a matter of debate, orally administered
tritiated CS is absorbed and found in plasma as high, low
and intermediate molecular weight metabolites11. Further-
more, CS shows a tropism for cartilagineous tissues in
rats and for knee tissues in humans, as demonstrated by
scintigraphic analysis with 99mTc-labeled CS11. When CS
was administered orally to patients as a single dose of
1200 mg/day in gastroresistant capsules, a time peak was
observed at 4 h and a maximum plasma concentration of
3.8 0.6 mg/ml was measured11. This level is within the
lower part of the concentration range used in the present
study (1, 10 and 100 mg/ml). However, no measurement
of plasma concentrations in long-term treated patients,
who generally received 1200 mg/day for at least 3 months,
has already been done. Further investigation is required to
determine the concentration levels, which are actually
achieved in synovial ﬂuid and cartilage treated patients.
One limitation of this study is that of steady-state levels of
mRNA do not necessarily reﬂect protein expression and ac-
tivity. However, mRNA measurements are generally good
indicators for proteins that are induced rather than constitu-
tively expressed, and simple procedures to estimate the ex-
pression and activity of several genes at the same time.
Furthermore, regarding the mechanism of action of CS,
our investigation did not address the possibility that a partof the exogenous IL-1b could bind to the CS added and be-
come inactivated. A recent study with modelized CS oligo-
saccharides tends to support the hypothesis that two sites
of interaction between IL-1b and some CS sequences might
be possible53. Therefore, we cannot exclude that the de-
crease of IL-1b effects could partly result from the speciﬁc
binding to CS. However, preliminary results from our labora-
tory suggest that CS directly activates chondrocyte signal-
ing pathways and may interfere with those induced by IL-1b.
In conclusion, our data demonstrate that CS can de-
crease the expression of genes encoding proteolytic
enzymes involved in cartilage degradation, including aggre-
canases, whereas it slightly stimulates aggrecan synthesis.
The compound also reduces the IL-1b up-regulation of
COX-2 mRNA, a crucial pro-inﬂammatory gene in joint dis-
eases. Furthermore, through its ability to restore the expres-
sion of TGF-bRII in chondrocytes, CS may enhance the
potential of these cells to counteract IL-1b deleterious ef-
fects on cartilage. Although CS efﬁcacy cannot be com-
pared to that of nonsteroidal anti-inﬂammatory drugs, its
effects on chondrocytes suggest that it can exert slight
chondroprotective and anti-inﬂammatory actions that could
have some beneﬁcial effect on OA cartilage.Acknowledgment
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